<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01359384</url>
  </required_header>
  <id_info>
    <org_study_id>KGU 84-11</org_study_id>
    <nct_id>NCT01359384</nct_id>
  </id_info>
  <brief_title>Bronchial Inflammation in Patients With Severe Immune Deficiency Under Immunoglobulin Treatment</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of the clinical trial is to gain a more substantial understanding of bronchial
      inflammation in patients with severe primary immundeficiency under immunoglobulin therapy. It
      is intended to characterize the systemical such as the bronchial inflammation (IL-1, IL-2,
      IL-6, IL-8, IL-17, TNF-a, NFkB, IFN-gamma, TGF-beta, TLR2 und TLR4)in children with severe
      immune deficiency in order to generate new treatment strategies based on the results.

      The methods being used for characterization purposes within this trial include specific lung
      function tests ( spirography, bodyplethysmographie w. helium) such as the analysis of eNO and
      eCO. Furthermore, sputum and serum samples are being analyzed by quantitative real-time
      polymerase chain reaction (PCR),(qRT-PCR) and by cytometric bead assay (CBA). Components of
      the innate immune system (mannose-binding protein, TLR recognition proteins and surfactant
      proteins) are genetically determined from sputum or blood respectively. In the conduct of the
      study the investigators will retrospectively and systematically evaluate the available
      high-resolution computed tomography (HRCT) studies of affected patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical trial contains a patient collective of 50 (6-60 years of age) that shall be
      eventually compared to a control group equal in age and gender. Both the patients and the
      healthy subjects are recruited from the outpatient clinic of Pediatric Allergy and
      Pulmonology.

      Methods and Work Programme:

      This study consists of two study visits (V1 and V2)

      V1:

        -  Measurement of nitric oxide in expired air (eNO)

        -  Measurement of carbon monoxide in the exhaled air (eCO)

        -  Lung function testing with spirography and bodyplethysmographie

        -  Blood test: blood count, CRP, RAST, serum inflammatory mediators, genetic markers of the
           non-specific pulmonary defense system

        -  Induced sputum for inflammatory mediators and microbiological investigations

      V2:

      *Unspecific bronchial provocation test with methacholine (PD20 FEV1 metacholine)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Immune Deficiency</condition>
  <arm_group>
    <arm_group_label>affected patients</arm_group_label>
    <description>25 patients suffering from severe immune deficiency under immunoglobulin therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-affected patients</arm_group_label>
    <description>25 matched controls not suffering from severe immune deficiency</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum and sputum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study is carried out in children and young adults (6-60 years of age). Both the
        patients (25) and the healthy subjects (25) are recruited from the outpatient clinic of the
        departement of Pediatric Allergy and Pulmonology and the departement of Pediatric Immune
        deficiency , University Clinic, JW Goethe University, Frankfurt/M, Germany
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent

          -  6 to 60 years of age

          -  known severe immune deficiency under immunoglobulin therapy/ no immune deficiency (
             depending on study group)

          -  ability to perform lung function tests and inhalation

        Exclusion Criteria:

          -  &lt; 6 and &gt; 60 years of age on the day of written informed consent

          -  acute illness with systemic or bronchial inflammation

          -  every chronic condition or infection (e.g. HIV, tuberculosis, malignancy)

          -  pregnancy

          -  known alcohol and/ or drug abuse

          -  Inability to understand the extent and scope of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Martin Rosewich, MD</last_name>
    <phone>+(49) 69 6301</phone>
    <phone_ext>5381</phone_ext>
    <email>Martin.Rosewich@kgu.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital, Goethe-University</name>
      <address>
        <city>Frankfurt a. Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Rosewich, MD</last_name>
      <email>Martin.Rosewich@kgu.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Sweinberg SK, Wodell RA, Grodofsky MP, Greene JM, Conley ME. Retrospective analysis of the incidence of pulmonary disease in hypogammaglobulinemia. J Allergy Clin Immunol. 1991 Jul;88(1):96-104.</citation>
    <PMID>2071789</PMID>
  </reference>
  <reference>
    <citation>de Gracia J, Vendrell M, Alvarez A, Pallisa E, Rodrigo MJ, de la Rosa D, Mata F, Andreu J, Morell F. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol. 2004 Jun;4(6):745-53.</citation>
    <PMID>15135316</PMID>
  </reference>
  <reference>
    <citation>Eickmeier O, Huebner M, Herrmann E, Zissler U, Rosewich M, Baer PC, Buhl R, Schmitt-Groh√© S, Zielen S, Schubert R. Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function. Cytokine. 2010 May;50(2):152-7. doi: 10.1016/j.cyto.2010.02.004. Epub 2010 Feb 23.</citation>
    <PMID>20181491</PMID>
  </reference>
  <reference>
    <citation>Touw CM, van de Ven AA, de Jong PA, Terheggen-Lagro S, Beek E, Sanders EA, van Montfrans JM. Detection of pulmonary complications in common variable immunodeficiency. Pediatr Allergy Immunol. 2010 Aug;21(5):793-805. doi: 10.1111/j.1399-3038.2009.00963.x. Epub 2009 Nov 13. Review.</citation>
    <PMID>19912551</PMID>
  </reference>
  <reference>
    <citation>Buehring I, Friedrich B, Schaaf J, Schmidt H, Ahrens P, Zielen S. Chronic sinusitis refractory to standard management in patients with humoral immunodeficiencies. Clin Exp Immunol. 1997 Sep;109(3):468-72.</citation>
    <PMID>9328124</PMID>
  </reference>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2011</study_first_submitted>
  <study_first_submitted_qc>May 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2011</study_first_posted>
  <last_update_submitted>May 23, 2011</last_update_submitted>
  <last_update_submitted_qc>May 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. med. Stefan Zielen</name_title>
    <organization>Johann Wolfgang Goethe University Hospitals</organization>
  </responsible_party>
  <keyword>severe primary immune deficieny</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

